KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bristol Myers Squibb (BMY) Asset Writedowns and Impairment (2016 - 2025)

Historic Asset Writedowns and Impairment for Bristol Myers Squibb (BMY) over the last 16 years, with Q3 2025 value amounting to $196.0 million.

  • Bristol Myers Squibb's Asset Writedowns and Impairment rose 4100.72% to $196.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.2 billion, marking a year-over-year increase of 20394.61%. This contributed to the annual value of $3.0 billion for FY2024, which is 106196.08% up from last year.
  • As of Q3 2025, Bristol Myers Squibb's Asset Writedowns and Impairment stood at $196.0 million, which was up 4100.72% from $2.0 billion recorded in Q4 2024.
  • Bristol Myers Squibb's Asset Writedowns and Impairment's 5-year high stood at $2.0 billion during Q4 2024, with a 5-year trough of $1.0 million in Q1 2024.
  • Its 5-year average for Asset Writedowns and Impairment is $282.4 million, with a median of $61.0 million in 2022.
  • As far as peak fluctuations go, Bristol Myers Squibb's Asset Writedowns and Impairment plummeted by 9860.07% in 2021, and later surged by 663448.28% in 2024.
  • Over the past 5 years, Bristol Myers Squibb's Asset Writedowns and Impairment (Quarter) stood at $15.0 million in 2021, then skyrocketed by 133.33% to $35.0 million in 2022, then fell by 17.14% to $29.0 million in 2023, then soared by 6634.48% to $2.0 billion in 2024, then crashed by 89.96% to $196.0 million in 2025.
  • Its last three reported values are $196.0 million in Q3 2025, $2.0 billion for Q4 2024, and $139.0 million during Q3 2024.